Literature DB >> 16791898

Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.

Rachel Brummel1, Tara L Roberts, Katryn J Stacey, Petar Lenert.   

Abstract

Mouse follicular B cells express TLR9 and respond vigorously to stimulation with single-stranded CpG-oligodeoxynucleotides (ODN). Surprisingly, follicular B cells do not respond to direct stimulation with other TLR9 ligands, such as bacterial DNA or class A(D) CpG-ODN capable of forming higher-order structures, unless other cell types are present. Here, we show that priming with interferons or with B cell-activating factor, or simultaneous co-engagement of the B cell receptor for antigen (BCR), can overcome this unresponsiveness. The effect of interferons occurs at the transcriptional level and is mediated through an autocrine/paracrine loop, which is dependent on IRF-1, IL-6 and IL-12 p40. We hypothesize that the lack of bystander activation of follicular B cells with more complex CpG ligands may be an important safety mechanism for avoiding autoimmunity. This will prevent resting B cells from responding to foreign or self-derived hypomethylated double-stranded CpG ligands unless these ligands are either delivered through the B cell receptor or under conditions where B cells are simultaneously co-engaged by activated plasmacytoid dendritic cells or TH1 cells. A corollary is that the heightened responsiveness of lupus B cells to TLR9-induced stimulation cannot be ascribed to unprimed follicular B cells, but is rather mediated by hypersensitive marginal zone B cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16791898     DOI: 10.1002/eji.200535734

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Phenotypic and functional heterogeneity of human memory B cells.

Authors:  Iñaki Sanz; Chungwen Wei; F Eun-Hyung Lee; Jennifer Anolik
Journal:  Semin Immunol       Date:  2008-02-06       Impact factor: 11.130

3.  Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes.

Authors:  Eliana Mariño; James L Richards; Keiran H McLeod; Dragana Stanley; Yu Anne Yap; Jacinta Knight; Craig McKenzie; Jan Kranich; Ana Carolina Oliveira; Fernando J Rossello; Balasubramanian Krishnamurthy; Christian M Nefzger; Laurence Macia; Alison Thorburn; Alan G Baxter; Grant Morahan; Lee H Wong; Jose M Polo; Robert J Moore; Trevor J Lockett; Julie M Clarke; David L Topping; Leonard C Harrison; Charles R Mackay
Journal:  Nat Immunol       Date:  2017-03-27       Impact factor: 25.606

4.  Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice.

Authors:  T Layer; A Steele; J A Goeken; S Fleenor; P Lenert
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

5.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

6.  IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.

Authors:  Timothy B Niewold; Jennifer A Kelly; Silvia N Kariuki; Beverly S Franek; Akaash A Kumar; Kenneth M Kaufman; Kenaz Thomas; Daniel Walker; Stan Kamp; Jacqueline M Frost; Andrew K Wong; Joan T Merrill; Marta E Alarcón-Riquelme; Mohammed Tikly; Rosalind Ramsey-Goldman; John D Reveille; Michelle A Petri; Jeffrey C Edberg; Robert P Kimberly; Graciela S Alarcón; Diane L Kamen; Gary S Gilkeson; Timothy J Vyse; Judith A James; Patrick M Gaffney; Kathy L Moser; Mary K Crow; John B Harley
Journal:  Ann Rheum Dis       Date:  2011-11-16       Impact factor: 19.103

7.  B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.

Authors:  Noam Jacob; Shunhua Guo; Alexis Mathian; Michael N Koss; Simona Gindea; Chaim Putterman; Chaim O Jacob; William Stohl
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

Review 8.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

9.  Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides.

Authors:  Ana M Avalos; Eicke Latz; Betty Mousseau; Sean R Christensen; Mark J Shlomchik; Frances Lund; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.